James Rolke - Revelation Biosciences CEO Director
| REVB Stock | USD 0.97 0.07 6.73% |
Insider
James Rolke is CEO Director of Revelation Biosciences
| Age | 55 |
| Address | 4660 La Jolla Village Drive, San Diego, CA, United States, 92122 |
| Phone | 650 800 3717 |
| Web | https://www.revbiosciences.com |
James Rolke Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Rolke against Revelation Biosciences stock is an integral part of due diligence when investing in Revelation Biosciences. James Rolke insider activity provides valuable insight into whether Revelation Biosciences is net buyers or sellers over its current business cycle. Note, Revelation Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Revelation Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Rolke over a year ago Acquisition by James Rolke of 2542 shares of Revelation Biosciences subject to Rule 16b-3 |
Revelation Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.5098) % which means that it has lost $0.5098 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7002) %, meaning that it created substantial loss on money invested by shareholders. Revelation Biosciences' management efficiency ratios could be used to measure how well Revelation Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 13, 2024, Return On Tangible Assets is expected to decline to -0.01. The current year's Return On Capital Employed is expected to grow to -1.24. The current year's Intangible Assets is expected to grow to about 3.2 M, whereas Total Assets are forecasted to decline to about 11.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Timothy Pigot | Aerovate Therapeutics | 53 | |
| Dr Roberts | Lyra Therapeutics | 55 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| BS CPA | Inhibrx | 42 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| Donald MBA | Lyra Therapeutics | 70 | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Mark Lappe | Inhibrx | 57 | |
| Laura Carter | Gossamer Bio | 57 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| Hunter MD | Aerovate Therapeutics | 58 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Quinn Deveraux | Inhibrx | N/A | |
Management Performance
| Return On Equity | -2.7 | ||||
| Return On Asset | -0.51 |
Revelation Biosciences Leadership Team
Elected by the shareholders, the Revelation Biosciences' board of directors comprises two types of representatives: Revelation Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revelation. The board's role is to monitor Revelation Biosciences' management team and ensure that shareholders' interests are well served. Revelation Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revelation Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Rolke, CEO Director | ||
| Carol Odle, Director Projects | ||
| Chester III, Chief Officer | ||
| Sandra Vedrick, Vice Relations |
Revelation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revelation Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.7 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | (2.37 M) | ||||
| Shares Outstanding | 3.76 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 1.17 % | ||||
| Number Of Shares Shorted | 41.24 K | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 2.70 X | ||||
| Price To Sales | 2.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (33.18) | Return On Assets (0.51) | Return On Equity (2.70) |
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.